300199 翰宇药业
已收盘 07-30 15:00:00
资讯
新帖
简况
长寿药NMN概念盘中拉升,翰宇药业涨5.48%
市场透视 · 07-22
长寿药NMN概念盘中拉升,翰宇药业涨5.48%
7月7日翰宇药业现1笔大宗交易 机构净卖出207.68万元
证券之星 · 07-07
7月7日翰宇药业现1笔大宗交易 机构净卖出207.68万元
54家公司发布半年报业绩预告:华银电力净利润预测同比增长4423%,翰宇药业预增1664%,渝开发预增784%(名单)
第一财经 · 07-06
54家公司发布半年报业绩预告:华银电力净利润预测同比增长4423%,翰宇药业预增1664%,渝开发预增784%(名单)
净利润大增1664%!翰宇药业连亏7年后靠“减肥神药”翻身
微博财经-财道工作室 · 07-02
净利润大增1664%!翰宇药业连亏7年后靠“减肥神药”翻身
翰宇药业:预计2025年上半年净利润1.42亿元至1.62亿元
证券之星 · 07-01
翰宇药业:预计2025年上半年净利润1.42亿元至1.62亿元
翰宇药业申请一种替尔泊肽的制备方法专利 极大地提高了生产效率
金融界 · 07-01
翰宇药业申请一种替尔泊肽的制备方法专利 极大地提高了生产效率
【化学制药板块持续走高,山河药辅、灵康药业涨停】 化学制药板块持续走高,山河药辅、灵康药业涨停,北陆药业、翰宇药业、永安药业、星昊医药、哈三联等跟涨。
金融界 · 07-01
【化学制药板块持续走高,山河药辅、灵康药业涨停】 化学制药板块持续走高,山河药辅、灵康药业涨停,北陆药业、翰宇药业、永安药业、星昊医药、哈三联等跟涨。
A股公告精选 | 翰宇药业(300199.SZ)、涛涛车业(301345.SZ)等股半年报业绩预喜
智通财经网 · 06-30
A股公告精选 | 翰宇药业(300199.SZ)、涛涛车业(301345.SZ)等股半年报业绩预喜
翰宇药业上涨5.46%,报18.34元/股
金融界 · 06-17
翰宇药业上涨5.46%,报18.34元/股
【翰宇药业:司美格鲁肽注射液减重适应症已完成三期临床全部受试者入组】 翰宇药业在互动平台上表示,公司的司美格鲁肽注射液按照2.2类进行上市申报,其中减重适应症于今年1月已完成三期临床全部受试者入组,目前正处于随访进行阶段,且项目已进入剂量维持期。未来三期临床完成后,公司将依据相关法规要求,整理完善临床试验数据后提交上市申请。
金融界 · 06-12
【翰宇药业:司美格鲁肽注射液减重适应症已完成三期临床全部受试者入组】 翰宇药业在互动平台上表示,公司的司美格鲁肽注射液按照2.2类进行上市申报,其中减重适应症于今年1月已完成三期临床全部受试者入组,目前正处于随访进行阶段,且项目已进入剂量维持期。未来三期临床完成后,公司将依据相关法规要求,整理完善临床试验数据后提交上市申请。
【CRO概念震荡走低 联化科技跌停】CRO概念震荡走低,联化科技跌停,万邦医药、河化股份、翰宇药业、睿智医药、昭衍新药等跟跌。
金融界 · 06-11
【CRO概念震荡走低 联化科技跌停】CRO概念震荡走低,联化科技跌停,万邦医药、河化股份、翰宇药业、睿智医药、昭衍新药等跟跌。
翰宇药业获得实用新型专利授权:“用于缓释生长抑素类似物的药物组合物制备装置”
证券之星 · 05-22
翰宇药业获得实用新型专利授权:“用于缓释生长抑素类似物的药物组合物制备装置”
翰宇药业(300199.SZ)签署多肽创新药物联合开发协议
智通财经 · 05-12
翰宇药业(300199.SZ)签署多肽创新药物联合开发协议
翰宇药业(300199.SZ):利拉鲁肽原料药获得韩国MFDS受理
智通财经 · 05-06
翰宇药业(300199.SZ):利拉鲁肽原料药获得韩国MFDS受理
【翰宇药业:全资子公司翰宇武汉通过国家高新技术企业重新认定】翰宇药业公告,全资子公司翰宇武汉于近日收到《高新技术企业证书》,发证时间为2024年12月16日,有效期为三年。翰宇武汉此前已按15%的企业所得税税率进行纳税申报及预缴,本次通过高新技术企业的重新认定不会对公司经营业绩产生重大影响。
金融界 · 04-30
【翰宇药业:全资子公司翰宇武汉通过国家高新技术企业重新认定】翰宇药业公告,全资子公司翰宇武汉于近日收到《高新技术企业证书》,发证时间为2024年12月16日,有效期为三年。翰宇武汉此前已按15%的企业所得税税率进行纳税申报及预缴,本次通过高新技术企业的重新认定不会对公司经营业绩产生重大影响。
翰宇药业4月29日现1笔大宗交易 成交金额220.77万元
新浪证券-红岸工作室 · 04-29
翰宇药业4月29日现1笔大宗交易 成交金额220.77万元
翰宇药业(300199)2025年一季报简析:营收净利润同比双双增长,短期债务压力上升
证券之星 · 04-26
翰宇药业(300199)2025年一季报简析:营收净利润同比双双增长,短期债务压力上升
翰宇药业(300199)3月31日股东户数5.73万户,较上期增加21.34%
证券之星 · 04-26
翰宇药业(300199)3月31日股东户数5.73万户,较上期增加21.34%
图解翰宇药业年报:第四季度单季净利润同比增58.34%
证券之星 · 04-25
图解翰宇药业年报:第四季度单季净利润同比增58.34%
翰宇药业(300199.SZ)发布一季度业绩,扭亏为盈至6986.84万元
智通财经 · 04-25
翰宇药业(300199.SZ)发布一季度业绩,扭亏为盈至6986.84万元
加载更多
公司概况
公司名称:
深圳翰宇药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-04-07
主营业务:
深圳翰宇药业股份有限公司的主营业务是多肽药物研发、生产和销售。公司的主要产品是多肽制剂、多肽原料药、小核酸、CDMO/CMO。
发行价格:
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":19.09,"timestamp":1753859001000,"preClose":20.07,"halted":0,"volume":117025724,"delay":0,"changeRate":-0.0488,"floatShares":706000000,"shares":883000000,"eps":-0.1016,"marketStatus":"已收盘","change":-0.98,"latestTime":"07-30 15:00:00","open":19.58,"high":19.99,"low":18.91,"amount":2282000000,"amplitude":0.0538,"askPrice":19.1,"askSize":2294,"bidPrice":19.09,"bidSize":3878,"shortable":0,"etf":0,"ttmEps":-0.1016,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753925400000},"marketStatusCode":5,"adr":0,"adjPreClose":20.07,"symbolType":"stock","openAndCloseTimeList":[[1753839000000,1753846200000],[1753851600000,1753858800000]],"highLimit":22.08,"lowLimit":18.06,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"isCdr":false,"pbRate":27.34,"roa":"--","roe":"11.39%","epsLYR":-0.2,"committee":0.377735,"marketValue":16861000000,"turnoverRate":0.1657,"status":1,"floatMarketCap":13483000000},"requestUrl":"/m/hq/s/300199","defaultTab":"news","newsList":[{"id":"2553283656","title":"长寿药NMN概念盘中拉升,翰宇药业涨5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553283656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553283656?lang=zh_cn&edition=full","pubTime":"2025-07-22 10:04","pubTimestamp":1753149856,"startTime":"0","endTime":"0","summary":"07月22日,长寿药NMN概念盘中拉升,截至10点04分,长寿药NMN概念整体指数上涨0.51%,报1154.640点。从个股上来看,该概念的成分股中,翰宇药业涨5.48%,德展健康、众生药业、国药现代涨幅居前。从资金上来看,截止发稿,长寿药NMN概念主力净流入为-2513.81万,其中翰宇药业受到资金热捧,主力净流入4978.92万;拉长时间线来看,该板块近20日主力资金净流入-44.54亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722100416954c1113&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722100416954c1113&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0020","BK0028","BK0070","BK0082","BK0239","600420","BK0010","BK0132","BK0188","BK0077","300199"],"gpt_icon":0},{"id":"2549582254","title":"7月7日翰宇药业现1笔大宗交易 机构净卖出207.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549582254","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549582254?lang=zh_cn&edition=full","pubTime":"2025-07-07 17:07","pubTimestamp":1751879250,"startTime":"0","endTime":"0","summary":"证券之星消息,7月7日翰宇药业发生大宗交易,交易数据如下:大宗交易成交价格18.88元,成交11万股,成交金额207.68万元,买方营业部为中国国际金融股份有限公司深圳分公司,卖方营业部为机构专用。近三个月该股共发生3笔大宗交易,合计成交4786.0手。该股近期无解禁股上市。截至2025年7月7日收盘,翰宇药业(300199)报收于18.88元,上涨2.11%,换手率22.33%,成交量157.7万手,成交额30.56亿元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070700022670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0028","300199","BK0239","BK0188","BK0077"],"gpt_icon":0},{"id":"2549320165","title":"54家公司发布半年报业绩预告:华银电力净利润预测同比增长4423%,翰宇药业预增1664%,渝开发预增784%(名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2549320165","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549320165?lang=zh_cn&edition=full","pubTime":"2025-07-06 19:58","pubTimestamp":1751803080,"startTime":"0","endTime":"0","summary":" 54家公司发布半年报业绩预告,部分预增股遭抢筹、市场聚焦TMT股。 部分个股发布业绩预增公告次日迎来股价大涨,反映场内资金正围绕中报行情做文章。Wind数据显示,有54家上市公司已发布2025年半年报业绩预告,21家预增、11家略增、4家续盈、3家扭亏、2家略减、5家首亏、1家续亏、3家预减,另有4家不确定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-07-06/doc-infepxhi7086188.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-07-06/doc-infepxhi7086188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600744","300199","000514"],"gpt_icon":0},{"id":"2548818558","title":"净利润大增1664%!翰宇药业连亏7年后靠“减肥神药”翻身","url":"https://stock-news.laohu8.com/highlight/detail?id=2548818558","media":"微博财经-财道工作室","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548818558?lang=zh_cn&edition=full","pubTime":"2025-07-02 20:20","pubTimestamp":1751458800,"startTime":"0","endTime":"0","summary":"而在此之前,翰宇药业扣非净利润已连亏7年。此番业绩大涨与翰宇药业一款仿制药在美上市有关。在此期间,翰宇药业陆续与大型药企Hikma签订合同,向后者独家供应利拉鲁肽注射液以开拓美国市场,累计已签署3.38亿元的订单。2019年因集采和行业竞争影响,翰宇药业营收腰斩至6.14亿元,此后缓慢增长至2023年再次下滑,2024年重新增长实现营收5.9亿元。利润方面,2018年至2024年,公司扣非净利润连续7年处于亏损状态。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2025-07-02/doc-infeawwa5562636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300199"],"gpt_icon":0},{"id":"2548926001","title":"翰宇药业:预计2025年上半年净利润1.42亿元至1.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548926001","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548926001?lang=zh_cn&edition=full","pubTime":"2025-07-01 20:49","pubTimestamp":1751374145,"startTime":"0","endTime":"0","summary":"证券之星消息,翰宇药业06月30日在投资者关系平台上答复投资者关心的问题。翰宇药业回复:公司已披露2025年上半年度业绩预告,预计实现归属于上市公司股东的净利润1.42亿元至1.62亿元,较去年同期大幅增长1470.82%至1663.89%,详请关注公司公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100035360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2548261140","title":"翰宇药业申请一种替尔泊肽的制备方法专利 极大地提高了生产效率","url":"https://stock-news.laohu8.com/highlight/detail?id=2548261140","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548261140?lang=zh_cn&edition=full","pubTime":"2025-07-01 12:02","pubTimestamp":1751342575,"startTime":"0","endTime":"0","summary":"金融界2025年7月1日消息,国家知识产权局信息显示,深圳翰宇药业股份有限公司申请一项名为“一种替尔泊肽的制备方法”的专利,公开号CN120230188A,申请日期为2023年12月。通过天眼查大数据分析,深圳翰宇药业股份有限公司共对外投资了13家企业,参与招投标项目710次,财产线索方面有商标信息308条,专利信息442条,此外企业还拥有行政许可132个。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/01120251404964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0028","BK0070","BK0077","BK0188","300199","BK0239"],"gpt_icon":0},{"id":"2548403630","title":"【化学制药板块持续走高,山河药辅、灵康药业涨停】 化学制药板块持续走高,山河药辅、灵康药业涨停,北陆药业、翰宇药业、永安药业、星昊医药、哈三联等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548403630","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548403630?lang=zh_cn&edition=full","pubTime":"2025-07-01 09:52","pubTimestamp":1751334762,"startTime":"0","endTime":"0","summary":"化学制药板块持续走高,山河药辅、灵康药业涨停,北陆药业、翰宇药业、永安药业、星昊医药、哈三联等跟涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/01095251401634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002900","BK1161","BK0033","BK0070","300452","300016","BK0060","BK1574","BK0086","BK0077","BK0239","BK1515","BK0188","01477","09939","BK1191","002365","BK0046","BK0177","BK0042","159938","BK0028","BK0056","300199","603669"],"gpt_icon":0},{"id":"2547092335","title":"A股公告精选 | 翰宇药业(300199.SZ)、涛涛车业(301345.SZ)等股半年报业绩预喜","url":"https://stock-news.laohu8.com/highlight/detail?id=2547092335","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547092335?lang=zh_cn&edition=full","pubTime":"2025-06-30 20:50","pubTimestamp":1751287845,"startTime":"0","endTime":"0","summary":"翰宇药业:上半年预盈1.42亿元-1.62亿元,原料药出口持续放量","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20250630/20250630205158_12651.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250630/20250630205158_12651.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1312116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"A股公告精选 | 翰宇药业(300199.SZ)、涛涛车业(301345.SZ)等股半年报业绩预喜","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0188","BK0077","300199","BK0279","BK0239","301345","BK0028","BK0070","159982","399300"],"gpt_icon":0},{"id":"2544093381","title":"翰宇药业上涨5.46%,报18.34元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2544093381","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544093381?lang=zh_cn&edition=full","pubTime":"2025-06-17 10:06","pubTimestamp":1750125986,"startTime":"0","endTime":"0","summary":"6月17日,翰宇药业盘中上涨5.46%,截至10:06,报18.34元/股,成交13.3亿元,换手率10.51%,总市值161.99亿元。截至3月31日,翰宇药业股东户数5.73万,人均流通股1.23万股。2025年1月-3月,翰宇药业实现营业收入3.1亿元,同比增长106.29%;归属净利润6986.84万元,同比增长595.45%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/17100651106629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0070","300199","BK0188","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2542566397","title":"【翰宇药业:司美格鲁肽注射液减重适应症已完成三期临床全部受试者入组】 翰宇药业在互动平台上表示,公司的司美格鲁肽注射液按照2.2类进行上市申报,其中减重适应症于今年1月已完成三期临床全部受试者入组,目前正处于随访进行阶段,且项目已进入剂量维持期。未来三期临床完成后,公司将依据相关法规要求,整理完善临床试验数据后提交上市申请。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542566397","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542566397?lang=zh_cn&edition=full","pubTime":"2025-06-12 12:23","pubTimestamp":1749702238,"startTime":"0","endTime":"0","summary":"翰宇药业在互动平台上表示,公司的司美格鲁肽注射液按照2.2类进行上市申报,其中减重适应症于今年1月已完成三期临床全部受试者入组,目前正处于随访进行阶段,且项目已进入剂量维持期。未来三期临床完成后,公司将依据相关法规要求,整理完善临床试验数据后提交上市申请。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/12122351023441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","03347","BK1576","BK0239","BK0077","BK1141","BK0070","BK0028","300199","BK0188"],"gpt_icon":0},{"id":"2542914373","title":"【CRO概念震荡走低 联化科技跌停】CRO概念震荡走低,联化科技跌停,万邦医药、河化股份、翰宇药业、睿智医药、昭衍新药等跟跌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542914373","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542914373?lang=zh_cn&edition=full","pubTime":"2025-06-11 11:09","pubTimestamp":1749611373,"startTime":"0","endTime":"0","summary":"CRO概念震荡走低,联化科技跌停,万邦医药、河化股份、翰宇药业、睿智医药、昭衍新药等跟跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/11110950996739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0004","BK0010","BK0239","BK0229","000953","BK0077","301520","BK1576","06127","BK0066","BK0188","BK0118","BK0216","300199","BK0028","BK0071","603127","BK1141","BK0070","002250","300149"],"gpt_icon":0},{"id":"2537292911","title":"翰宇药业获得实用新型专利授权:“用于缓释生长抑素类似物的药物组合物制备装置”","url":"https://stock-news.laohu8.com/highlight/detail?id=2537292911","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537292911?lang=zh_cn&edition=full","pubTime":"2025-05-23 02:14","pubTimestamp":1747937672,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示翰宇药业新获得一项实用新型专利授权,专利名为“用于缓释生长抑素类似物的药物组合物制备装置”,专利申请号为CN202421481060.5,授权日为2025年5月23日。解决了用于缓释生长抑素类似物的组合物生产过程的溶解不完全、易混入气泡、残留严重、设备密封性和混合效果差的问题。本申请提升了用于缓释生长抑素类似物的药物组合物制备装置的性能。今年以来翰宇药业新获得专利授权7个,较去年同期减少了12.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052300000649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0070","BK0028","300199","BK0077"],"gpt_icon":0},{"id":"2534250262","title":"翰宇药业(300199.SZ)签署多肽创新药物联合开发协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2534250262","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534250262?lang=zh_cn&edition=full","pubTime":"2025-05-12 19:10","pubTimestamp":1747048254,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰宇药业(300199.SZ)公告,2025年5月9日,公司召开第六届董事会第四次会议,审议通过了《关于签署的议案》。同意公司与深圳碳云智肽药物科技有限公司(简称“碳云智肽”)就GLP-1R/GIPR/GCGR三重激动剂多肽创新药物签署联合开发协议。基于前期合作成果,为进一步推动项目进展,双方拟深化合作,计划联合开发多肽创新药物,多肽药物给药剂型包括但不限于注射剂、口服制剂等,应用于体重控制等代谢性疾病治疗领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1292131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK1161","BK0077","BK0239","BK1574","159992","06978","300199","BK0188","BK0070"],"gpt_icon":0},{"id":"2533631907","title":"翰宇药业(300199.SZ):利拉鲁肽原料药获得韩国MFDS受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2533631907","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533631907?lang=zh_cn&edition=full","pubTime":"2025-05-06 21:28","pubTimestamp":1746538104,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰宇药业(300199.SZ)发布公告,近日,公司全资子公司翰宇药业(武汉)有限公司的利拉鲁肽原料药获得韩国食品药品安全厅(以下简称“MFDS”)的审批受理。据悉,利拉鲁肽是人胰高血糖素样肽-1(Glucagon-like peptide-1,GLP-1)的类似物,GLP-1受体是重要的药物靶点,具有多种生理功能:血糖依赖性促进胰岛素分泌、保护胰岛β细胞、延迟胃排空以降低食欲等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300199","BK0188","BK0077","BK0028","BK0239","BK0070"],"gpt_icon":0},{"id":"2531702376","title":"【翰宇药业:全资子公司翰宇武汉通过国家高新技术企业重新认定】翰宇药业公告,全资子公司翰宇武汉于近日收到《高新技术企业证书》,发证时间为2024年12月16日,有效期为三年。翰宇武汉此前已按15%的企业所得税税率进行纳税申报及预缴,本次通过高新技术企业的重新认定不会对公司经营业绩产生重大影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531702376","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531702376?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:41","pubTimestamp":1746002467,"startTime":"0","endTime":"0","summary":"翰宇药业公告,全资子公司翰宇武汉于近日收到《高新技术企业证书》,发证时间为2024年12月16日,有效期为三年。翰宇武汉此前已按15%的企业所得税税率进行纳税申报及预缴,本次通过高新技术企业的重新认定不会对公司经营业绩产生重大影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/30164150044125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300199","BK0077","BK0188","BK0070","BK0239","BK0028"],"gpt_icon":0},{"id":"2531920124","title":"翰宇药业4月29日现1笔大宗交易 成交金额220.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531920124","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531920124?lang=zh_cn&edition=full","pubTime":"2025-04-29 17:40","pubTimestamp":1745919600,"startTime":"0","endTime":"0","summary":" 4月29日,翰宇药业收跌2.11%,收盘价为13.92元,发生1笔大宗交易,合计成交量15.86万股,成交金额220.77万元。 第1笔成交价格为13.92元,成交15.86万股,成交金额220.77万元,溢价率为0.00%,买方营业部为机构专用,卖方营业部为中信证券股份有限公司泉州温陵北路证券营业部。 进一步统计,近3个月内该股累计发生8笔大宗交易,合计成交金额为2237万元。该股近5个交易日累计下跌1.83%,主力资金合计净流出1.26亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-04-29/doc-ineuvnxv5693416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","300199","BK0188","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2530720951","title":"翰宇药业(300199)2025年一季报简析:营收净利润同比双双增长,短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2530720951","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530720951?lang=zh_cn&edition=full","pubTime":"2025-04-27 06:37","pubTimestamp":1745707051,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期翰宇药业发布2025年一季报。截至本报告期末,公司营业总收入3.1亿元,同比上升106.29%,归母净利润6986.84万元,同比上升595.45%。本报告期翰宇药业短期债务压力上升,流动比率达0.31。本次财报公布的各项数据指标表现尚佳。融资分红:公司上市14年以来,累计融资总额25.15亿元,累计分红总额4.17亿元,分红融资比为0.17。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042700001910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2530440531","title":"翰宇药业(300199)3月31日股东户数5.73万户,较上期增加21.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530440531","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530440531?lang=zh_cn&edition=full","pubTime":"2025-04-26 17:14","pubTimestamp":1745658871,"startTime":"0","endTime":"0","summary":"证券之星消息,近日翰宇药业披露,截至2025年3月31日公司股东户数为5.73万户,较12月31日增加1.01万户,增幅为21.34%。在化学制药行业个股中,翰宇药业股东户数高于行业平均水平,截至3月31日,化学制药行业平均股东户数为3.15万户。从股价来看,2024年12月31日至2025年3月31日,翰宇药业区间涨幅为21.49%,在此期间股东户数增加1.01万户,增幅为21.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600011985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0077","BK0239","300199","BK0070"],"gpt_icon":0},{"id":"2530168802","title":"图解翰宇药业年报:第四季度单季净利润同比增58.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530168802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530168802?lang=zh_cn&edition=full","pubTime":"2025-04-26 01:14","pubTimestamp":1745601276,"startTime":"0","endTime":"0","summary":"证券之星消息,翰宇药业2024年年报显示,公司主营收入5.9亿元,同比上升36.82%;归母净利润-1.74亿元,同比上升66.21%;扣非净利润-2.4亿元,同比上升59.44%;其中2024年第四季度,公司单季度主营收入2.15亿元,同比上升620.69%;单季度归母净利润-1.39亿元,同比上升58.34%;单季度扣非净利润-1.46亿元,同比上升58.83%;负债率80.15%,投资收益154.59万元,财务费用1.14亿元,毛利率57.09%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600000506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2530132108","title":"翰宇药业(300199.SZ)发布一季度业绩,扭亏为盈至6986.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530132108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530132108?lang=zh_cn&edition=full","pubTime":"2025-04-25 22:13","pubTimestamp":1745590407,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰宇药业(300199.SZ)发布2025年第一季度报告,该公司营业收入为3.1亿元,同比增长106.29%。归属于上市公司股东的净利润为6986.84万元。归属于上市公司股东的扣除非经常性损益的净利润为6555万元。基本每股收益为0.08元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0077","BK0239","BK0188","300199","BK0070"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753875548325,"stockEarnings":[{"period":"1week","weight":0.0613},{"period":"1month","weight":0.2351},{"period":"3month","weight":0.4554},{"period":"6month","weight":0.7793},{"period":"1year","weight":1.1792},{"period":"ytd","weight":0.557}],"compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":0.0542},{"period":"3month","weight":0.1008},{"period":"6month","weight":0.1105},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.077}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"57273人(较上一季度增加21.34%)","perCapita":"12331股","listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","registeredCapital":"88324万元","survey":" 深圳翰宇药业股份有限公司的主营业务是多肽药物研发、生产和销售。公司的主要产品是多肽制剂、多肽原料药、小核酸、CDMO/CMO。","listedPrice":30.19},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}